Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

nepepe Jan. 23 at 12:23 AM

$PHIO don’t sleep on it

0 · Reply

nepepe Jan. 23 at 12:23 AM

$PHIO loaded up

0 · Reply

DosGatos Jan. 22 at 11:03 PM

$PHIO

0 · Reply

AJWW316 Jan. 22 at 9:58 PM

$PHIO echo this, did anyone listen in ? Had a little trickle up today so it can’t of been anything negative.

0 · Reply

dln101 Jan. 22 at 8:46 PM

$PHIO this low float bio itching for $SXTP $IOBT moves 🤔💪🔥🚀

0 · Reply

Sidoti Jan. 22 at 8:03 PM

Phio Pharmaceuticals Corp. ($PHIO) Management Team presented today at the Sidoti Micro-Cap Virtual Conference. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_AZ-3eOfHQZaq86JVCZZUuQ

0 · Reply

gronekty7 Jan. 22 at 7:24 PM

$PHIO anything good said at the conference?

0 · Reply

DERDER Jan. 22 at 7:23 PM

$PHIO

0 · Reply

AJWW316 Jan. 22 at 7:23 PM

$PHIO

0 · Reply

CertaTrader Jan. 22 at 5:24 PM

$PHIO

0 · Reply

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 15, 2026, 8:45 AM EST - 7 days ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Dec 23, 2025, 8:45 AM EST - 4 weeks ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025, 11:30 AM EST - 2 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 17, 2025, 8:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 2 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 10:30 AM EST - 2 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 2 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 5 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 6 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 6 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 9 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 10 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 11 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

nepepe Jan. 23 at 12:23 AM

$PHIO don’t sleep on it

0 · Reply

nepepe Jan. 23 at 12:23 AM

$PHIO loaded up

0 · Reply

DosGatos Jan. 22 at 11:03 PM

$PHIO

0 · Reply

AJWW316 Jan. 22 at 9:58 PM

$PHIO echo this, did anyone listen in ? Had a little trickle up today so it can’t of been anything negative.

0 · Reply

dln101 Jan. 22 at 8:46 PM

$PHIO this low float bio itching for $SXTP $IOBT moves 🤔💪🔥🚀

0 · Reply

Sidoti Jan. 22 at 8:03 PM

Phio Pharmaceuticals Corp. ($PHIO) Management Team presented today at the Sidoti Micro-Cap Virtual Conference. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_AZ-3eOfHQZaq86JVCZZUuQ

0 · Reply

gronekty7 Jan. 22 at 7:24 PM

$PHIO anything good said at the conference?

0 · Reply

DERDER Jan. 22 at 7:23 PM

$PHIO

0 · Reply

AJWW316 Jan. 22 at 7:23 PM

$PHIO

0 · Reply

CertaTrader Jan. 22 at 5:24 PM

$PHIO

0 · Reply

Smith_84 Jan. 22 at 1:23 PM

$PHIO

0 · Reply

zannnn Jan. 22 at 11:46 AM

$PHIO

0 · Reply

SlothMan2026 Jan. 21 at 7:44 PM

$CAPS had a nice little shakeout today, a solid buying opportunity after the CEO cut his pay to $1 to right this ship & get it where it needs to go in 2026 🤙 I wish I had the guts to get shares closer to $.60 but I still added a chunk after seeing strength. I’m just shy of 230k shares at this point, no pumping & dumping here. Anyone wanna match me? https://capstoneholdingcorp.com/capstone-executes-2-0-million-cost-rationalization-establishes-clear-path-to-positive-ebitda/ $BHAT $MYSZ $NWTG $PHIO

0 · Reply

WildernessRefuge Jan. 21 at 5:47 PM

$PHIO PHIO has a webinar on Sidoti tomorrow afternoon (January 22, 2026). I have always found CEO Bitterman to be upfront and honest. He has always detailed the capital raise needs of the company on Sidoti Road Shows in the past, and I would expect an update from Bitterman about possible dilution (remember there is a 50% overhang of warrants here already). Here is a link to sign up:https://sidoti.zoom.us/webinar/register/WN_AZ-3eOfHQZaq86JVCZZUuQ#/registration I do not work for Sidoti, or PHIO. I have been following PHIO for about a year and have bought and sold stock over this past year, I currently own no shares.

0 · Reply

DosGatos Jan. 21 at 3:35 PM

$PHIO Tammy is still holding with a target of 0.70 that is correct!

0 · Reply

Nik_CA Jan. 21 at 3:17 PM

$PHIO @MS_Tammy are you still holding PHIO with a target of $7?

1 · Reply

Stonkey Jan. 21 at 2:39 PM

$PHIO Under a dollar in 3.......2.......1........ANOTHER REVERSE SPLIT ALOUND COLNEEEEEEEEEEEEEEELLLLL!!!!!

0 · Reply

HaroldH Jan. 21 at 11:55 AM

$PHIO Why is Phio price dropping? 1) The press release yesterday contained no new information over that released on November 3, 2025. 2) The press release together with the two CEO buys of $5000 suggest that the CEO is under pressure from warrant holders to do something to raise the price. 3) The CEO probably has no ammunition left because it will take some time to analyse the data and get the next stage approved by the FDA. My guess, and it is a guess, is that we are talking about a couple of months before there is a market moving release of data. Time is money.

3 · Reply

AJWW316 Jan. 21 at 11:48 AM

$PHIO Some bullish PR today at the conference would be nice

0 · Reply

SqueezeRib Jan. 21 at 11:09 AM

$PHIO

0 · Reply

zannnn Jan. 21 at 10:27 AM

$PHIO

0 · Reply

KuruHabesha Jan. 20 at 10:10 PM

$PHIO In with a starter!

0 · Reply

Market Cap	11.20M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	312,400
Avg Vol	420,058
Day's Range	N/A - N/A
Shares Out	10.76M
Stochastic %K	33%
Beta	0.89
Analysts	Sell
Price Target	$14.00